Research

Hormonal

Tirzepatide requires GIP receptor (GIPR) activation to stimulate insulin secretion in human islets, as blocking GIPR consistently reduces this response.

Tirzepatide's effectiveness in lowering blood sugar relies on its ability to activate the GIP receptor, not just the GLP-1 receptor. In human tissue, blocking the GIP receptor stops tirzepatide from stimulating insulin, proving this second pathway is essential for its full benefit.

GoodSupportsHIGH confidence
in human islets, antagonizing GIPR activity consistently decreases the insulin response to tirzepatide.
Kimberley El et al. · Nature Metabolism · 2023

Why this rating

High-quality in vitro human islet data with multiple donors, though lacking direct in vivo human receptor blockade trials.

Source

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

Kimberley El et al. · Nature Metabolism · 2023

DOI 10.1038/s42255-023-00811-0

mechanism_onlyCited 109×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →